Apomorphine in the treatment of Parkinson's disease.
Motor fluctuations, refractory to conventional medical management, are one of the most troubling aspects of Parkinson's disease. Apomorphine is a dopaminergic agent that has been known to the medical community for more than a century, but has only recently been developed to treat such motor fluctuations. In this article, the authors review the historical background, structure, mechanism of action, pharmacologic properties, clinical trials, indications and side effects, as well as avenues of further research, of apomorphine.
Menon
Rukmini
R
Duke University Medical Center, Durham, NC 27705, USA.
Stacy
Mark
M
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001058:Apomorphine / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000075202:Contraindications; D004333:Drug Administration Routes; D020820:Dyskinesias / Q000188:drug therapy; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
D000978:Antiparkinson Agents; D001058:Apomorphine